What is capsular contracture?
Capsular contracture occurs when the scar tissue capsule around a breast implant tightens. It can make the breast feel firm or hard and may cause visible distortion, asymmetry, implant displacement, tenderness, or pain.
Capsular contracture occurs when the scar tissue capsule around a breast implant tightens. It can make the breast feel firm or hard and may cause pain, visible distortion, asymmetry, or a higher implant position. Surgeons classify severity using Baker Grades I through IV. Treatment is individualized after an appropriate evaluation.
Medically reviewed by Robert Whitfield, MD, FACS on September 4, 2026
A capsule is the scar tissue that normally forms around a breast implant. Capsular contracture occurs when that capsule tightens and changes how the breast feels or looks. Symptoms can include increasing firmness, hardness, pressure, pain, visible distortion, asymmetry, or an implant that sits higher than before.
Grade I: the breast feels soft and looks natural.
Grade II: the breast feels slightly firm but looks normal.
Grade III: the breast feels firm and has visible distortion or an abnormal appearance.
Grade IV: the breast feels hard, is painful or tender, and looks abnormal. [1]
The Baker scale describes clinical severity. It does not identify why the capsule changed, prove that an implant ruptured, or determine which treatment is appropriate. Those questions require an individual history, examination, and imaging or other testing when clinically indicated.
Clinical context: The capsule is fibrous tissue that forms around an implant, and its composition and behavior can vary among patients. Researchers are studying local immune activity and bacterial signals, but current findings do not establish a single cause of chronic inflammation or contracture in an individual patient.
Capsular contracture is classified by the Baker Grade system, which describes severity based on what the patient feels and what the surgeon observes.
The Baker scale uses appearance, firmness, and pain to describe four clinical grades. It is useful shorthand, but it is not a laboratory test and does not identify the cause of a patient's symptoms.
| Baker Grade | How It Feels | What You May See | Pain or Discomfort | Typical Next Step |
|---|---|---|---|---|
| Grade I | Soft, like a natural breast | Natural appearance | Usually none | Routine follow-up or observation |
| Grade II | Slightly firm | Usually looks normal | Often none | Clinical review if new, changing, or concerning |
| Grade III | Firm | Visible distortion or abnormal shape | May be uncomfortable; pain is not required | Individualized surgical evaluation is commonly discussed |
| Grade IV | Hard | Clearly abnormal or distorted appearance | Painful or tender | Prompt individualized surgical evaluation |
Baker grading is a clinical assessment. It does not determine the exact operation, establish implant rupture, or replace an individualized examination.
An evaluation helps clarify the symptoms, implant history, anatomy, goals, and available options. It does not mean surgery is required or that every patient is a candidate.
Grade III and Grade IV findings are generally the most clinically significant because they involve visible distortion, pain, or both. Grade I and some Grade II findings may not require an operation, but a new or changing breast should be assessed in the context of the patient's history and goals.
| Symptom | Description |
|---|---|
| Firmness or hardness | The breast feels unusually firm or rock-hard, different from its natural soft texture |
| Change in breast shape | The implant rides high, sits asymmetrically, or the breast contour is distorted |
| Tightness or pressure | A sensation of squeezing or pressure around the breast and chest wall |
| Pain | Aching, burning, sharp, intermittent, or persistent pain at the implant site |
| Visible asymmetry | One breast looks or sits differently than the other |
| High-riding implant | The implant has shifted upward, creating an unnatural appearance |
Important: Capsular contracture can develop months or years after implant placement — sometimes a decade or more after surgery. If you notice any of these changes, even long after your original procedure, they warrant evaluation.
Evaluation begins with the patient's symptoms, timing, implant history, prior operations, and goals. A physical examination assesses firmness, tenderness, breast shape, implant position, skin and soft tissue, and differences between sides. Baker grade is assigned clinically rather than by a website quiz or photograph.
Imaging may be considered when the history or examination raises questions about implant integrity, fluid, a mass, or another condition. Ultrasound or magnetic resonance imaging can provide information about selected implant complications, but imaging does not replace the clinical Baker assessment and does not by itself prescribe an operation.
The discussion may include observation, capsulotomy, partial or total capsulectomy, implant removal without replacement, implant exchange, pocket or plane change, and breast-shape options such as lift or fat transfer. The appropriate plan depends on anatomy, symptoms, operative history, safety, preferences, and informed consent.
Rapid swelling, a new breast or armpit mass, marked redness, drainage, fever, sudden severe pain, or a rapid change in breast shape should be evaluated promptly. These findings are not automatically capsular contracture and may require assessment for other implant or breast conditions. [1]
Capsular contracture is considered multifactorial and is not fully understood. Proposed contributors include the wound-healing response, implant and surgical factors, bleeding, inflammation, and microbial signals. Biofilm is one hypothesis under study, but current evidence does not establish it as the cause in an individual patient.
A biofilm is a structured microbial community within a matrix. Biofilms can occur on medical devices, and investigators have studied whether they may contribute to some breast-implant complications. DNA detection alone does not demonstrate a mature biofilm, viable organisms, or infection.
Laboratory methods answer different questions: culture assesses growth under specified conditions, molecular assays detect targeted nucleic-acid material, and microscopy or other methods may evaluate structure. None of these findings, by itself, proves why a particular capsule hardened or what treatment that patient needs.
Bacteremia means viable bacteria are present in the bloodstream. It may be transient and asymptomatic, but it can also accompany or progress to a bloodstream infection. Transient bacteremia can occur with oral hygiene, dental or medical procedures, and some infections; its clinical significance varies by context. [7]
Hematogenous seeding has been proposed as one possible route by which microorganisms could reach an implant, but human evidence does not establish that routine transient bacteremia causes late capsular contracture. Guidance about antibiotic prophylaxis for selected cardiac conditions should not be extrapolated to breast implants. Patients should follow their own clinicians' dental and medical recommendations rather than taking antibiotics for an unproven implant indication.
Dr. Whitfield published a retrospective analysis of 694 submitted capsule and associated tissue specimens. Of these, 203 of 694 submitted capsule or associated tissue specimens (29%) returned positive molecular findings under the study method, which reported 103 taxa labels. These molecular findings require clinical context. [5]
| Research Metric | Finding |
|---|---|
| Total specimens analyzed | 694 submitted capsule and associated tissue specimens |
| Testing method | Endpoint PCR screening followed by targeted next-generation sequencing of 16S rRNA V1–V2 and ITS3–4 targets, with a multispecies qPCR panel |
| Submitted capsule or associated tissue specimens with positive molecular findings under the study method | 203 of 694 (29%) |
| Reported taxa labels | 103 taxa labels, with lineage resolution limited by the assay and reference data |
| Paired conventional-culture comparison | Not performed on all 694 submitted specimens; no all-specimen sensitivity comparison can be inferred |
| Publication | Microorganisms, September 2024, Vol. 12(9):1830 |
| Status | Published retrospective submitted-specimen series |
Research interpretation: Optional PCR and targeted sequencing may report bacterial DNA fragments and related classifications. Those findings do not establish viability, infection, colonization, contamination, biofilm behavior, immune effect, or symptom causation. They also do not establish species presence where the assay cannot resolve lineage.
The results describe assay classifications in a retrospective submitted-specimen series, not a prevalence estimate for all implant capsules. A detected taxonomic label may generate a research hypothesis, but it cannot show whether an organism was alive, where the detected material originated, or whether it affected that patient's capsule or symptoms.
What this means for patients: Molecular findings cannot diagnose infection or assign a cause of capsular contracture. History, examination, imaging when indicated, operative findings, pathology, and microbiology must be interpreted together.
This is the question capsular contracture research has struggled to answer for decades. Two women can receive the same implant from the same manufacturer, placed by the same surgeon using the same technique — and one develops severe contracture within two years while the other has soft, comfortable implants a decade later.
Tissue-level molecular research is one area being explored, but it does not provide one established explanation for why contracture develops in a particular patient.
A 2025 study published in Plastic and Reconstructive Surgery used whole-transcriptome RNA sequencing to compare gene-expression patterns in capsule tissue with and without capsular contracture. The assay denominator was 51 breasts from 50 women; the analysis reported 1,500 differentially expressed genes, including 873 upregulated and 627 downregulated genes. This transcriptome association is hypothesis-generating and does not establish causation, diagnose an individual patient, measure biofilm burden, or direct treatment. [6]
| Finding | Data |
|---|---|
| Total differentially expressed genes | 1,500 |
| Genes upregulated in capsular contracture | 873 |
| Genes downregulated | 627 |
| Immune pathways activated | T cell, B cell, and plasma cell activation — pathways associated with organ allograft rejection |
The authors reported enrichment of gene-expression pathways that are also labeled in transplant-rejection research. Shared pathway labels do not mean that a breast implant is being rejected like a transplanted organ, and they do not establish a treatment directive.
These are similarities in gene-expression pathway labels, not evidence of true allograft rejection.
A breast implant is not transplanted donor tissue. The study's pathway findings should not be interpreted as literal transplant rejection, an individual diagnosis, or a treatment directive.
The study supports an association between capsular contracture and different gene-expression patterns in the sampled tissue. It does not establish that bacteria or biofilm caused those patterns, and it did not measure bacteremia, symptom severity, response to conservative care, or recurrence.
These group-level findings cannot explain why a particular patient develops Grade IV disease. Individual variation remains an area of research within a multifactorial condition.
Grade III and Grade IV capsular contracture often prompt discussion of surgery, but no single operation is best for every patient. Options may include capsulotomy, partial or total capsulectomy, implant removal, implant exchange, pocket change, and breast-shape procedures. The plan depends on anatomy, symptoms, implant history, safety, goals, and informed consent. [4]
Published evidence is largely observational and heterogeneous. Recurrence can occur after different approaches, and current evidence does not show that complete capsulectomy is universally superior or guarantees removal of all capsule tissue, microbial material, or a proposed immune trigger.
Capsulectomy means surgical removal of some or all of the capsule. Partial and total procedures have different extents, and safe removal may be limited by adherence to the chest wall or other anatomy. A surgeon should explain the intended extent, alternatives, and procedure-specific risks without promising complete removal or freedom from recurrence.
Learn about all capsulectomy options →
For significant capsular contracture without suspected malignancy, an attempt to remove the implant and capsule together without disrupting the capsule is generally described as a total intact capsulectomy, not an en bloc capsulectomy. The extent and technique of capsule removal are selected individually based on anatomy, operative findings, safety, symptoms, and informed consent.
Breast Surgery Collaborative Community terminology reserves en bloc capsulectomy for removal of the capsule with a margin of uninvolved tissue in patients with suspected or established breast implant-associated malignancy after appropriate medical workup. Intact removal cannot always be performed safely, and no technique guarantees complete removal, symptom resolution, or freedom from recurrence. [8]
Review capsulectomy terminology and indications →
Some patients who undergo explant choose fat transfer breast augmentation. No implant capsule forms when no implant remains. Fat retention is variable, however, and recognized risks include resorption, fat necrosis, oil cysts, calcification, infection, contour irregularity, and possible staged procedures. Retained fat may behave like other body fat, but there is no permanence guarantee.
Capsular contracture can recur when an implant remains or a new implant is placed. Published recurrence estimates vary widely because studies differ in Baker grade, primary versus revision surgery, implant plane and type, procedure, follow-up duration, and patient selection. A systematic review found limited high-level evidence for choosing one management strategy for every patient. [4]
Recurrence risk should be discussed for the specific plan under consideration. Implant exchange, capsulotomy, partial or total capsulectomy, plane change, acellular dermal matrix, implant removal without replacement, and reconstructive choices each involve different tradeoffs. No approach guarantees that contracture, pain, or another complication will not occur.
Dr. Whitfield may submit removed capsule or associated tissue for pathology and optional molecular testing when clinically appropriate. Endpoint PCR, targeted sequencing, and qPCR can detect selected nucleic-acid targets, subject to sampling, assay, lineage-resolution, and reference-database limits.
A molecular result does not establish viability, infection, colonization, contamination, biofilm behavior, immune effect, or symptom causation in a specific patient. Results are considered with the clinical history, examination, operative findings, pathology, and other testing rather than used as a stand-alone diagnosis or treatment directive.
| Dr. Whitfield's Approach | Detail |
|---|---|
| Capsule removal technique | Extent and technique selected individually; en bloc terminology reserved for suspected or established implant-associated malignancy |
| Specimen testing | Pathology and optional molecular testing considered in clinical context |
| Research foundation | Retrospective series: 203 of 694 submitted capsule or associated tissue specimens (29%) returned positive molecular findings under the study method; 103 taxa labels |
| Implant exchange for contracture | Discussed individually with recurrence uncertainty, alternatives, and tradeoffs |
| Combined procedures | Capsulectomy and fat transfer breast augmentation may be performed together in one surgery for appropriately selected patients after individualized evaluation |
Capsular contracture occurs when the scar tissue capsule around a breast implant tightens. It can make the breast feel firm or hard and may cause visible distortion, asymmetry, implant displacement, tenderness, or pain.
Patients may notice increasing firmness, tightness, pressure, tenderness, pain, or a breast that feels different from the other side. The implant may also appear higher, rounder, or visibly distorted.
Baker Grade IV is defined by a hard, painful breast with an abnormal appearance. Grade III has visible distortion and may be uncomfortable, but pain is not required for the Grade III classification.
Mild findings may be observed when they are stable and not troubling the patient. Increasing firmness, pain, distortion, a change in implant position, or uncertainty about the cause should be evaluated by a qualified clinician.
Progression varies. Changes may develop over months or years, remain stable, or become more noticeable. A page or photograph cannot determine an individual patient's progression, so new or worsening findings deserve clinical assessment.
No home method has been shown to reliably reverse established capsular contracture. Patients should not aggressively massage a painful or changing breast unless their own surgeon specifically recommends it for their situation.
Yes. Recurrence has been reported after different treatments. The risk depends on the operation, whether an implant remains or is replaced, the surgical setting, anatomy, healing, follow-up time, and other individual factors.
Coverage varies by plan, implant history, symptoms, reconstruction status, and the reason for surgery. The practice can provide clinical documentation when appropriate, but the patient should confirm benefits and authorization requirements directly with the insurer.
This page uses FDA patient-safety information, professional-society education, peer-reviewed evidence, and Dr. Whitfield's published capsule research. References support general education and do not replace individualized medical advice.
Dr. Whitfield is a board-certified plastic surgeon in Austin, Texas. His clinical focus includes breast implant removal, capsulectomy, revision breast surgery, and fat-transfer options. He is an author of the cited 2024 submitted-specimen capsule series. Research findings are presented with their limitations and are not used as a stand-alone diagnosis or treatment directive.
Medically reviewed by Robert Whitfield, MD, FACS on September 4, 2026
Austin and Out-of-Town Patients
Dr. Whitfield evaluates implant history, prior operations, symptoms, breast anatomy, imaging when indicated, and personal goals. The evaluation is a clinical and surgical planning visit, not an online diagnostic test and not a promise that surgery will be recommended.
Confidential evaluations are available for patients in Austin and for patients planning travel to Texas.